ProQR Therapeutics (PRQR) Return on Capital Employed (2014 - 2023)
ProQR Therapeutics recorded quarterly Return on Capital Employed of 30.05% in Q4 2023, up 4.22% quarter-over-quarter from 31.37% in Q3 2023, and up 2391.0% year-over-year from 1.21% in Q4 2022.
ProQR Therapeutics' Return on Capital Employed history runs 9 years deep, the most recent figure standing at 30.05% for Q4 2023.
- In Q4 2023, Return on Capital Employed rose 2391.0% year-over-year to 30.05%; the TTM figure through Dec 2023 stood at 30.05% (up 2391.0% YoY), while the FY2025 annual figure was 43.0%, down 1639.0% from the prior year.
- Return on Capital Employed came in at 30.05% for Q4 2023 at ProQR Therapeutics, up from 31.37% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 0.0% in Q1 2019 to a low of 71.54% in Q3 2019.
- A 5-year average of 37.29% and a median of 38.06% in 2023 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed tumbled 9031 bps in 2019 and surged 5854 bps in 2021, its largest moves.
- ProQR Therapeutics' Return on Capital Employed stood at 65.62% in 2019, then jumped by 33 bps to 43.71% in 2020, then gained by 24 bps to 33.17% in 2021, then tumbled by 63 bps to 53.96% in 2022, then surged by 44 bps to 30.05% in 2023.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 30.05%, 31.37%, and 37.31% for Q4 2023, Q3 2023, and Q2 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | ProQR Therapeutics | 174.11 Mn | 66.54 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -30.05% |
| Sep 30, 2023 | -31.37% |
| Jun 30, 2023 | -37.31% |
| Mar 31, 2023 | -38.80% |
| Dec 31, 2022 | -53.96% |
| Sep 30, 2022 | -58.47% |
| Jun 30, 2022 | -42.12% |
| Mar 31, 2022 | -36.01% |
| Dec 31, 2021 | -33.17% |
| Sep 30, 2021 | -35.79% |
| Jun 30, 2021 | -0.10% |
| Mar 31, 2021 | -0.08% |
| Dec 31, 2020 | -43.71% |
| Sep 30, 2020 | -52.19% |
| Jun 30, 2020 | -56.85% |
| Mar 31, 2020 | -58.62% |
| Dec 31, 2019 | -65.62% |
| Sep 30, 2019 | -71.54% |
| Jun 30, 2019 | 0.00% |
| Mar 31, 2019 | 0.00% |
| Dec 31, 2018 | 0.02% |
| Sep 30, 2018 | 0.02% |
| Jun 30, 2018 | 90.31% |
| Mar 31, 2018 | 90.23% |
| Dec 31, 2016 | -0.11% |
| Mar 31, 2015 | -17.12% |
| Dec 31, 2014 | -11.92% |